Bristol Myers Squibb opened 2026 with steady top-line growth and strong performance from its expanding portfolio of newer medicines, even as legacy drugs continued to face expected pressure from generics.

 

The company reported first-quarter revenues of $11.5 billion, up 3% year over year (or 1% excluding foreign exchange), driven by accelerating demand across its Growth Portfolio.

 

“We are off to a good start in 2026, with first quarter results reflecting sustained momentum across our Growth Portfolio and disciplined execution throughout the business,” said Christopher Boerner, board chair and chief executive officer, Bristol Myers Squibb. 

 

“With multiple pivotal data readouts and opportunities ahead, we remain focused on advancing our differentiated pipeline and translating this progress into meaningful outcomes for patients and shareholders.”

 

The company’s Growth Portfolio delivered $6.2 billion in revenue, surging 12% (9% Ex-FX), powered by strong gains from key therapies including Camzyos, Breyanzi, and Reblozyl.

 

Momentum was especially strong across newer oncology and specialty drugs: Breyanzi jumped 56% worldwide; Camzyos soared nearly 97% worldwide; Opdualag and Reblozyl also posted double-digit global growth.

 

The Legacy Portfolio generated $5.3 billion, down 6%, as continued generic erosion weighed on older treatments. While Eliquis remained a standout with 16% global growth, major declines in drugs like Revlimid (-63%) and Sprycel (-58%) offset that strength.

 

Geographic performance was mixed: U.S. revenue was $7.8 billion, down 1%; International revenue came to $3.7 billion, up 11%.

 

Bristol Myers Squibb reiterated its full-year guidance, expecting 2026 revenues of approximately $46.0–$47.5 billion and non-GAAP EPS of $6.05–$6.35, with both metrics now trending toward the upper end of the range.